BioVie Inc. (BIVI)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Cuong V. Do
Employees:
10
2120 COLORADO AVE., SUITE 230, LOS ANGELES, CA 90404
310-444-4300

BioVie Inc. engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trials for Alzheimer's, Parkinson's and multiple myeloma and prostate cancer.

Data derived from most recent annual or quarterly report
Market Cap 0 Shares Outstanding0 Avg 30-day Volume 415.308 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-14.82
Price to Revenue0.0 Debt to Equity2.1348 EBITDA-133.347 Million
Price to Book Value11.3672 Operating Margin0.0 Enterprise Value59.253 Million
Current Ratio5.272 EPS Growth-6.411 Quick Ratio5.184
1 Yr BETA 0.803 52-week High/Low 14.38 / 1.33 Profit Margin0.0
Operating Cash Flow Growth-379.816 Altman Z-Score-31.9756 Free Cash Flow to Firm -94.932 Million

Are you looking for this stock instead?

View SEC Filings from BIVI instead.

View recent insider trading info

Funds Holding BIVI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BIVI

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

PEIZER TERREN S

  • Director
  • 10% Owner
65,000 2022-11-23 1

GORLIN STEVE

  • Director
84,240 2022-11-23 2

BERMAN RICHARD J

  • Director
45,178 2022-11-23 2

ROGICH SIGMUND

  • Director
55,000 2022-11-23 2

READING CHRISTOPHER EVP NEUROSCIENCE R&D

  • Officer
39,624 2022-11-23 1

HARIRI ROBERT J

  • Director
34,240 2022-11-23 2

DO CUONG V CEO & PRESIDENT

  • Officer
  • Director
234,848 2022-11-23 1

LANG JAMES PAUL

  • Director
68,622 2022-11-23 2

SHERMAN MICHAEL EDWARD

  • Director
75,000 2022-11-23 2

MARKHAM PENELOPE EVP LIVER CIRRHOSIS R&D

  • Officer
50,317 2022-11-23 1

KIM JOANNE WENDY CHIEF FINANCIAL OFFICER

  • Officer
41,624 2022-11-23 1

AHLEM CLARENCE N. EVP NEUROSCIENCE PRODUCT DEV.

  • Officer
39,624 2022-11-23 1

PALUMBO JOSEPH M CHIEF MEDICAL OFFICER

  • Officer
39,624 2022-11-23 2

ADAMS JONATHAN M EVP LIVER CIRRHOSIS PROGRAMS

  • Officer
48,630 2022-02-02 1

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
BIOVIE INC BIVI 2023-01-27 22:15:03 UTC -56.6625 60.9825 400000
BIOVIE INC BIVI 2023-01-27 21:45:04 UTC -56.6625 60.9825 400000
BIOVIE INC BIVI 2023-01-27 21:15:04 UTC -56.6625 60.9825 400000
BIOVIE INC BIVI 2023-01-27 20:45:03 UTC -56.6625 60.9825 400000
BIOVIE INC BIVI 2023-01-27 20:15:04 UTC -56.6625 60.9825 400000
BIOVIE INC BIVI 2023-01-27 19:45:03 UTC -56.6625 60.9825 400000
BIOVIE INC BIVI 2023-01-27 19:15:03 UTC -56.6625 60.9825 400000
BIOVIE INC BIVI 2023-01-27 18:45:04 UTC -56.6625 60.9825 400000
BIOVIE INC BIVI 2023-01-27 18:15:03 UTC -56.6625 60.9825 400000
BIOVIE INC BIVI 2023-01-27 17:45:03 UTC -56.6625 60.9825 400000
BIOVIE INC BIVI 2023-01-27 17:15:04 UTC -56.6625 60.9825 400000
BIOVIE INC BIVI 2023-01-27 16:45:03 UTC -56.9346 61.2546 400000
BIOVIE INC BIVI 2023-01-27 16:15:03 UTC -56.9346 61.2546 400000
BIOVIE INC BIVI 2023-01-27 15:45:03 UTC -56.9346 61.2546 400000
BIOVIE INC BIVI 2023-01-27 15:15:04 UTC -56.9346 61.2546 400000
BIOVIE INC BIVI 2023-01-27 14:45:04 UTC -56.9346 61.2546 400000
BIOVIE INC BIVI 2023-01-27 14:15:03 UTC -56.9346 61.2546 400000
BIOVIE INC BIVI 2023-01-27 13:45:03 UTC -58.5768 62.8968 400000
BIOVIE INC BIVI 2023-01-27 13:15:03 UTC -58.5768 62.8968 400000
BIOVIE INC BIVI 2023-01-27 12:45:03 UTC -58.5768 62.8968 400000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund BIVI -800.0 shares, $-1992.0 2022-09-30 N-PORT

No recent transactions

*** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

Elevate your investments